Strong Cyp3a4 And P-Glycoprotein Inducers Interactions

Avoid concomitant use of P-gp and strong CYP3A4 inhibitors with everolimus due to increased drug exposure.

Source: NLP:everolimus

Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase lenacapavir plasma concentrations.

Source: NLP:lenacapavir sodium

Concomitant use may decrease paliperidone exposure. Avoid during dosing interval if possible; consider paliperidone extended-release tablets if necessary.

Source: NLP:paliperidone palmitate